Guy Yachin, BSc., MBA
Co-Founder & CEO
Prof. Cullen Taniguchi, M.D,
Co-Founder & CMO
Board-certified radiation oncologist he is an Assistant Professor in Radiation Oncology at MD Anderson Cancer Center, specializing in treating gastrointestinal malignancies, with a clinical focus on unresectable pancreatic cancer.
Dr. Michael Shtein, Ph.D, MBA
Co-Founder & Executive Chairman
Board of directors
Dr Thomas Duthy
Over 18 years direct financial market and medical device industry experience. Currently Executive Director and CEO of Nemean Group, a boutique corporate advisory, investor relations company based in Adelaide. Advisory/IR role(s) since 2019 with 7 ASX-listed companies, including $100 million sale of Nova Eye Medical (ASX:EYE) laser business to Lumibird in 2020. Former Global Head of Investor Relations and Corporate Development at ASX 100/200 Company Sirtex Medical Limited (ASX: SRX), which sold for $1.9 billion in late 2018. Also spent 10 years as an analyst at Taylor Collison, specialising in Healthcare and Biotechnology companies. Currently an Executive Director of Invex Therapeutics Limited (ASX:IXC).
Mr. Eyal Lifschitz
Eyal Lifschitz is a business founder and entrepreneur with years of experience establishing and managing medical technology companies and their business development efforts. Eyal was involved as a founder and a manger in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. and as a director of Given Imaging (NASDAQ: GIVN).
He holds an LLB from the Academic Center for Law and Science.
Mr. Doron Eldar
Result-focused entrepreneur with more than a decade of experience in senior leadership roles and is currently a Melbourne-based partner at venture capital fund SIBF.
Mr Eldar has extensive experience scaling innovative tech companies globally, formulating effective go-to-market strategies and driving market awareness for private and public tech companies.
Doron is also a venture partner at Oxen9 and a Director at Dotz Nano (ASX:DTZ), Electric Global, Livia and others.
To be announced
Proposed Chairman of the Board
Scientific team and Advisors
Dr. Zan Fleming, M.D.
Expert in Pharmaceutical R&D for more than 30 years, Responsible the development of known products. Served as Associate Director in the Innovative Pharma R&D of TEVA, Taro Pharmaceutical and various pharmaceutical firms.
Danit Holds B.F.E&B (Bachelor of Food Engineering and Biotechnology) from the Technion Institute, Haifa, and M.Sc in Pharmaceutical Chemistry at the Bar-Ilan University and B.Sc in Chemistry (especially in Organic Chemistry) at the Tel-Aviv University, Israel. Danit Issued dozens of patents worldwide and published articles.
Mr. Ofer Doron
Mr. Doron was the Manging Director of Lahav Research Institute (the largest large animals CRO in Israel) for 13 years. He was involved in the development of many medical devices and Pharmaceutical products. Mr. Doron serves today as a cosultant to various companies, he joined Xerient Pharma in 2020.
Prof. Daniel D. Von Hoff M.D.
Chief Medical Advisor
Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts